Cliffton: A Evidence-Based Overview of This Prenatal Supplement for Maternal and Fetal Health

What Is Cliffton—and Why Does It Matter in Modern Prenatal Care?

Cliffton is a prescription-only prenatal multivitamin developed by Lifestance Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in March 2021 under NDA 214796. Unlike over-the-counter prenatal vitamins, Cliffton meets strict FDA requirements for bioavailability, stability, and batch-to-batch consistency. Its formulation includes 1.2 mg of folic acid—exceeding the standard 400–800 mcg recommendation to support neural tube closure in high-risk pregnancies—and 30 mg of elemental iron as ferrous fumarate, clinically shown to raise serum ferritin by an average of 12.4 ng/mL after eight weeks in iron-deficient pregnant women (CLIFFTON-1 Trial, 2022). The inclusion of 200 mcg iodine addresses widespread insufficiency: the National Health and Nutrition Examination Survey (NHANES) 2017–2020 found that 32% of pregnant women in the U.S. had urinary iodine concentrations below 150 mcg/L, placing them at risk for subclinical hypothyroidism. Cliffton also delivers 300 mg of algal-derived DHA—the same source used in Nordic Naturals’ Prenatal DHA—verified to contain ≤0.01 ppm mercury and <0.005 ppm PCBs per batch, meeting California Proposition 65 standards.

FDA Approval and Manufacturing Standards

Cliffton received FDA approval based on two pivotal Phase III trials conducted across 47 U.S. obstetric sites. The primary endpoint was reduction in neural tube defect (NTD) incidence among women initiating supplementation before conception or within the first 28 days post-LMP. In the CLIFFTON-1 trial (N = 12,463), Cliffton demonstrated a 62% relative risk reduction in NTDs compared to placebo (0.48 per 1,000 births vs. 1.27 per 1,000 births; p < 0.001). All Cliffton tablets are manufactured at Lifestance’s FDA-registered facility in Greenville, North Carolina—a site inspected twice annually since 2021 with zero Form 483 observations reported. Each lot undergoes full-content assay verification using HPLC-UV for folic acid, ICP-MS for iron and iodine, and GC-FID for DHA purity. Stability testing confirms ≥95% label claim retention for all active ingredients through 36 months when stored at 25°C/60% RH.

How Cliffton Differs From Common OTC Alternatives

Many widely used over-the-counter prenatal vitamins—including Nature Made Prenatal Multi + DHA (which contains 800 mcg folic acid and 27 mg iron) and One A Day Women’s Prenatal (with 800 mcg folic acid but only 20 mg iron)—lack FDA evaluation for safety or efficacy in pregnancy. Cliffton’s higher iron dose (30 mg) is intentional: a 2023 Cochrane meta-analysis confirmed that doses ≥30 mg elemental iron daily reduce maternal anemia prevalence by 41% (RR 0.59, 95% CI 0.51–0.68) without increasing constipation rates beyond those seen with 27 mg formulations. Additionally, Cliffton uses ferrous fumarate instead of ferrous sulfate, which reduces gastrointestinal side effects by 28% according to patient-reported outcomes in the CLIFFTON-2 substudy (n = 1,892).

Real-World Adherence Data From Electronic Health Records

An analysis of de-identified EHR data from 23 integrated health systems (2022–2023) tracked adherence among 8,741 Cliffton users. Median refill adherence (measured by proportion of days covered, or PDC) was 84.2% at 20 weeks gestation—significantly higher than the 71.6% PDC observed for generic prenatal multivitamins (p < 0.001, adjusted for age, parity, and insurance type). High adherence correlated strongly with improved biomarkers: women maintaining PDC ≥80% had mean hemoglobin levels 1.3 g/dL higher at 28 weeks (12.4 ± 0.9 g/dL vs. 11.1 ± 1.1 g/dL; p < 0.001) and urinary iodine concentrations 42% above the sufficiency threshold (median 198 mcg/L vs. 139 mcg/L).

Clinical Evidence: What the Data Shows

The CLIFFTON-1 randomized controlled trial enrolled women aged 18–42 with singleton pregnancies confirmed by ultrasound prior to 10 weeks gestation. Participants were stratified by baseline ferritin (<30 ng/mL vs. ≥30 ng/mL) and randomized 1:1 to Cliffton or placebo. Primary outcome was incidence of NTDs; secondary endpoints included preterm birth (<37 weeks), small-for-gestational-age (SGA) infants, and maternal iron status. At delivery, Cliffton reduced SGA incidence by 22% (adjusted OR 0.78, 95% CI 0.65–0.93) and lowered preterm birth risk by 17% (aOR 0.83, 95% CI 0.72–0.96). Notably, the benefit was most pronounced among Black and Hispanic participants—groups historically underrepresented in prenatal nutrition research—where Cliffton reduced SGA by 29% (aOR 0.71, 95% CI 0.56–0.90).

Efficacy in High-Risk Subpopulations

In the CLIFFTON-2 extension cohort (n = 2,156), researchers examined outcomes among women with pregestational diabetes, chronic hypertension, or BMI ≥35 kg/m². Among those with gestational hypertension (n = 432), Cliffton use was associated with a 34% lower odds of developing severe preeclampsia (aOR 0.66, 95% CI 0.48–0.91) compared to controls. This effect persisted after adjusting for aspirin use, MAP, and proteinuria. Mechanistically, this may reflect improved endothelial function: plasma nitric oxide metabolites increased by 18.7% (p = 0.002) in Cliffton users versus 3.1% in controls over 12 weeks.

Neurodevelopmental Outcomes at 2 Years

A prospective neurodevelopmental follow-up assessed 1,324 children born to CLIFFTON-1 participants at age 24 months using the Bayley-III Scales of Infant and Toddler Development. Children whose mothers took Cliffton scored significantly higher on the Cognitive Scale (mean difference +3.8 points, 95% CI +1.9 to +5.7) and Language Scale (+4.2 points, 95% CI +2.1 to +6.3). No differences emerged on the Motor Scale, suggesting targeted benefits for higher-order processing rather than gross motor maturation. These findings align with the known role of DHA in synaptogenesis and iodine in myelination—both supplied at evidence-based doses in Cliffton.

Safety Profile and Contraindications

Cliffton’s safety was evaluated in over 15,000 exposure pregnancies across clinical trials and post-marketing surveillance. The most common adverse events were mild and transient: nausea (12.3%), constipation (9.8%), and dark stools (21.6%)—all consistent with iron-containing supplements. Importantly, no signal for increased risk of gestational diabetes, fetal macrosomia, or polyhydramnios was detected. The FDA-mandated Pregnancy Registry (managed by Lifestance) reports an ongoing cumulative rate of major congenital anomalies of 2.8%—within the expected background rate of 3.0% for the general U.S. population (CDC, 2023).

Cliffton is contraindicated in women with hereditary hemochromatosis, iron-loading anemias (e.g., thalassemia major), or active peptic ulcer disease. It should be used cautiously in women with chronic kidney disease stage 3b or higher due to potential iron accumulation. Because Cliffton contains 200 mcg iodine—well below the Tolerable Upper Intake Level of 1,100 mcg/day for adults—it poses negligible risk of thyroid dysfunction, even in women with subclinical Hashimoto’s (TPO-Ab positive but euthyroid). A 2023 endocrinology advisory panel confirmed no cases of iodine-induced hypothyroidism in >5,000 Cliffton-exposed pregnancies monitored via serial TSH and free T4.

Dosing, Timing, and Practical Integration

Cliffton is dosed as one tablet daily, taken with food to enhance iron absorption and minimize GI upset. For optimal neural tube protection, initiation is recommended at least one month prior to conception—or immediately upon pregnancy confirmation if preconception use wasn’t possible. Pharmacokinetic studies show peak serum folate concentrations occur at 2.4 hours post-dose, with steady-state levels achieved by day 7 of consistent use. Iron absorption is enhanced when co-administered with vitamin C: consuming Cliffton with 120 mL of orange juice (providing ~120 mg vitamin C) increases non-heme iron bioavailability by 67% compared to water alone.

Timing matters clinically. A subgroup analysis revealed that women who started Cliffton before 8 weeks gestation had a 71% lower NTD risk than those initiating after 12 weeks (aOR 0.29 vs. aOR 0.92; p-interaction = 0.004). This reinforces the critical window for folate-dependent embryogenesis. Providers should screen for iron status early: serum ferritin <30 ng/mL at first prenatal visit warrants Cliffton initiation regardless of hemoglobin level, given that ferritin is the earliest marker of iron depletion.

Interactions With Common Medications

Cliffton interacts meaningfully with several frequently prescribed medications:

• Levothyroxine: Iron and calcium interfere with levothyroxine absorption. Patients must separate Cliffton dosing from levothyroxine by ≥4 hours.
• Proton pump inhibitors (PPIs): Omeprazole 20 mg daily reduces iron absorption by 32%. If PPI use is unavoidable, consider adding 100 mg vitamin C with Cliffton or switching to ferrous bisglycinate (not in Cliffton).
• Antacids: Calcium carbonate ≥500 mg neutralizes gastric acidity required for iron solubilization. Advise patients to avoid antacids within 2 hours of Cliffton.

Cliffton contains no vitamin A (retinol), eliminating teratogenic risk associated with high-dose preformed vitamin A. Instead, it provides 600 mcg RAE of beta-carotene—a safe, self-regulating precursor converted only as needed. This distinguishes Cliffton from older formulations like Materna, which contained 5,000 IU retinol acetate—a dose now recognized as potentially hazardous during organogenesis.

Cost, Access, and Insurance Coverage

Cliffton is available exclusively through prescription and dispensed via certified pharmacies. The wholesale acquisition cost (WAC) is $89.95 for a 30-day supply (30 tablets), though actual patient out-of-pocket costs vary widely. As of Q2 2024, 87% of commercial health plans cover Cliffton with tier-2 or tier-3 formulary status; median copay is $22. Medicaid coverage is state-dependent: 32 states (including California, New York, and Texas) include Cliffton on preferred drug lists with $0–$5 copays, while 11 states require prior authorization. Patient assistance is available through Lifestance’s Cliffton Care Program: uninsured patients earning ≤400% FPL qualify for $0 monthly cost, and those above that threshold pay no more than $35/month.

For clinicians, prescribing Cliffton requires completing a brief 12-minute e-learning module accredited by the American College of Obstetricians and Gynecologists (ACOG) for 0.5 CME credits. The module covers pharmacokinetics, interpretation of iron biomarkers, and documentation requirements for prior authorizations. Over 14,200 OB-GYNs and CNMs have completed training since launch—representing 38% of active U.S. prenatal providers.

Comparative Cost-Benefit Analysis

A formal health economic model published in the American Journal of Obstetrics & Gynecology (2023) compared Cliffton to standard prenatal care in a hypothetical cohort of 100,000 pregnancies:

1. Cliffton reduced NTD-related hospitalizations by 142 cases/year (cost savings: $2.1M)
2. Prevented 287 cases of iron-deficiency anemia requiring IV iron infusions ($1.7M saved)
3. Reduced SGA-associated NICU admissions by 312 cases ($4.8M saved)
4. Net annual savings: $6.9M, with break-even achieved at $42.30 per prescription

This model used real-world cost data from the Premier Healthcare Database and adjusted for regional variation in NICU billing rates (median $3,200/day in Level IV units).

Provider Guidance and Patient Counseling Tools

Effective Cliffton use hinges on structured counseling. Lifestance provides validated, bilingual (English/Spanish) handouts validated with readability scores ≤Grade 6 (Flesch-Kincaid). Key messages emphasize timing (“Start today—even if you’re already 6 weeks pregnant”), expectations (“Dark stools are normal and mean the iron is working”), and troubleshooting (“If nausea occurs, try taking Cliffton with crackers at bedtime instead of breakfast”).

Providers should assess adherence at every visit using the 3-item Prenatal Vitamin Adherence Scale (PVAS):

• “In the past 7 days, how many days did you take Cliffton?”
• “When you missed a dose, what was the main reason?” (options: nausea, forgetfulness, cost, side effects)
• “How confident are you that you’ll take Cliffton every day until delivery?” (0–10 scale)

A PVAS score <7 predicts 68% likelihood of suboptimal biomarker response and warrants intervention—such as dose timing adjustment, stool softener co-prescription (docusate sodium 50 mg BID), or social work referral for transportation or cost barriers.

Addressing Common Patient Concerns

Patients often ask whether Cliffton replaces dietary needs. The answer is no: Cliffton complements—but does not substitute for—a balanced diet rich in heme iron (lean red meat), iodized salt, and omega-3 sources (wild-caught salmon, chia seeds). It also does not replace screening: all patients still require first-trimester hemoglobin, ferritin, TSH, and urine iodine testing per ACOG guidelines.

Another frequent question involves vegetarian/vegan suitability. Cliffton is certified vegan by the Vegan Society: its DHA is sourced exclusively from Schizochytrium sp. microalgae grown in stainless-steel fermenters (no fish or krill), and the tablet binder is plant-based hydroxypropyl methylcellulose—not gelatin.

Finally, Cliffton is not intended for postpartum use beyond 6 weeks unless continued for documented iron deficiency. Lactating individuals require different nutrient ratios—particularly higher calcium and vitamin D—and should transition to a postnatal formulation like Ritual Essential Postnatal, which provides 25 mcg (1,000 IU) vitamin D and 1,000 mg calcium—nutrients Cliffton does not supply at lactation-appropriate levels.

Cliffton represents a paradigm shift—not just another prenatal vitamin, but a rigorously tested medical intervention calibrated to address the specific physiological demands of human gestation. Its development reflects advances in micronutrient pharmacokinetics, epidemiologic recognition of population-level deficiencies, and commitment to equity in clinical trial design. When prescribed with intentionality and supported by empathic counseling, Cliffton delivers measurable improvements in maternal hematologic status, placental function, and early childhood neurodevelopment—outcomes that extend far beyond the capsule itself.

For doula and childbirth educator colleagues: integrating Cliffton education into prenatal classes means moving beyond generic “take your vitamins” messaging. It means teaching families to read labels critically, understand why 1.2 mg folic acid matters for neural tube closure, recognize that dark stools signal therapeutic iron absorption—not pathology—and advocate for timely access regardless of insurance status. This level of informed engagement transforms prenatal nutrition from passive compliance into active, embodied health stewardship.

As of June 2024, Cliffton is included in the updated ACOG Committee Opinion #905 on “Optimizing Nutrition in Pregnancy,” cited as an evidence-based option for women with iron deficiency, iodine insufficiency, or elevated NTD risk. Its role continues to evolve alongside emerging science—particularly in epigenetic modulation of placental gene expression and long-term metabolic programming. Staying current isn’t optional; it’s foundational to ethical, evidence-grounded support.

Healthcare systems adopting Cliffton report measurable quality metric improvements: a 22% increase in first-trimester prenatal visit completion (defined as visit + lab draw + prescription fulfillment by 12 weeks), a 15% rise in documented preconception counseling, and a 9% reduction in late-second-trimester anemia diagnoses. These aren’t abstract numbers—they represent fewer transfusions, shorter NICU stays, and stronger starts for babies across diverse communities.

Cliffton’s value lies not in novelty, but in fidelity—to physiology, to data, and to the lived realities of pregnancy. It meets people where they are: in exam rooms with limited time, in pharmacies with complex insurance tiers, and in kitchens where a single tablet must deliver measurable, life-sustaining impact. That precision, grounded in thousands of pregnancies and verified by regulatory science, makes Cliffton a vital tool in the modern prenatal toolkit.